References
[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. DOI:
10.1080/02688697.2018.1500521[2] Brown AM, et al. Ion permeation and conduction in a human recombinant 5-HT3 receptor subunit (h5-HT3A). J Physiol. 1998 Mar 15;507 ( Pt 3):653-65. DOI:
10.1111/j.1469-7793.1998.653bs.x[3] Barann M, et al. Recombinant human 5-HT3A receptors in outside-out patches of HEK 293 cells: basic properties and barbiturate effects. Naunyn Schmiedebergs Arch Pharmacol. 2000 Sep;362(3):255-65. DOI:
10.1007/s002100000288[4] Wildeboer KM, et al. Ondansetron results in improved auditory gating in DBA/2 mice through a cholinergic mechanism. Brain Res. 2009 Dec 1;1300:41-50. DOI:
10.1016/j.brainres.2009.08.075[5] Khedhaier A, et al. Circadian rhythms in toxic effects of the serotonin antagonist ondansetron in mice. Chronobiol Int. 2003 Nov;20(6):1103-16. DOI:
10.1081/cbi-120025532[6] Umathe SN, et al. The 5-HT3 receptor antagonist, ondansetron, blocks the development and expression of ethanol-induced locomotor sensitization in mice. Behav Pharmacol. 2009 Feb;20(1):78-83. DOI:
10.1097/FBP.0b013e3283242ff4[7] Doggrell SA, et al. Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. Expert Opin Drug Saf. 2013 May;12(3):421-31. DOI:
10.1517/14740338.2013.780026[8] INEKE VAN WIJNGAARDEN. Development of high-affinity 5-HT3 receptor antagonists. Structure-affinity relationships of novel 1,7-annulated indole derivatives. 1[J]. Journal of Medicinal Chemistry, 1993, 36 23: 3693-3699. DOI:
10.1021/jm00075a026[9] A. BUTLER. Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors[J]. British Journal of Pharmacology, 1988, 94 2: 397-412. DOI:
10.1111/j.1476-5381.1988.tb11542.x[10] R. STABLES . Antiemetic properties of the 5HT3-receptor antagonist, gr38032f[J]. Cancer treatment reviews, 1987, 14 3: Pages 333-336. DOI:
10.1016/0305-7372(87)90026-0[11] DEEPALI GUPTA Yeshwant K Mahesh Radhakrishnan. Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: Possible implication of serotonergic system[J]. European journal of pharmacology, 2014, 744: Pages 59-66. DOI:
10.1016/j.ejphar.2014.09.041